Phase III trials now collect an average of 5.9 million data points per protocol, and that figure has grown roughly 11% every year since 2020. That single statistic captures something the industry has been slow to name plainly: complexity is no longer a feature of ambitious trials, it is the baseline condition of all of them.
The growth didn’t start in 2020. Tufts CSDD data show that Phase III data point volumes jumped from roughly 929,000 in 2012 to 3.56 million by 2020, before the current acceleration. Layered on top, Phase III protocols now carry 37% more endpoints and 42% more procedures than they did a decade ago. Narrower eligibility criteria and more diverse data sources compound both. Sites that could once manage monitoring with periodic on-site visits now generate data streams that traditional oversight was never designed to handle.
The operational consequence is straightforward: more data does not automatically mean better data. A 2024 survey found that 39% of sponsors named protocol complexity as a primary driver of rising costs, which nearly half of respondents identified as their top concern. Volume without directed oversight produces noise. A monitoring approach calibrated to flag everything flags nothing useful, which is exactly the gap CluePoints frames as the argument for statistical, risk-based quality management. FDA’s April 2023 guidance on risk-based monitoring reinforced that the agency expects sponsors to use centralized, data-driven oversight rather than simply adding site visits to compensate for protocol weight.
The number to watch is the annual growth rate, not the current snapshot. At 11% per year, data volumes double roughly every seven years. A site management model adequate for 5.9 million points per trial becomes inadequate around 2033 without structural changes to how data are prioritized and reviewed. Sponsors who treat complexity as a temporary condition to be tolerated will find the math working against them well before that.
Source link: https://cluepoints.com/trial-complexity-is-the-new-normal/
Moe Alsumidaie is Chief Editor of The Clinical Trial Vanguard. Moe holds decades of experience in the clinical trials industry. Moe also serves as Head of Research at CliniBiz and Chief Data Scientist at Annex Clinical Corporation.
